{"nctId":"NCT01226459","briefTitle":"Clinical Trial in Females for Female Pattern Hair Loss","startDateStruct":{"date":"2010-09"},"conditions":["Androgenetic Alopecia"],"count":404,"armGroups":[{"label":"Minoxidil Foam","type":"EXPERIMENTAL","interventionNames":["Drug: 5% Minoxidil Topical Foam"]},{"label":"Vehicle Foam","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle Topical Foam"]}],"interventions":[{"name":"5% Minoxidil Topical Foam","otherNames":["Not yet marketed"]},{"name":"Vehicle Topical Foam","otherNames":["Vehicle Control (Placebo)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* females, age 18 or older in general good health\n* exhibits female pattern hair loss\n* signs and dates an informed consent document\n* agrees to use an adequate method of birth control; if of childbearing potential\n* shows a negative urine pregnancy test at Screening Visit\n* is willing to maintain the same hair style, hair color, and hair regimen throughout the study\n* is willing and able to comply with scheduled visits, treatment plan, laboratory tests and other trial procedures\n\nExclusion Criteria:\n\n* hypersensitivity to the (study product), or any ingredients of the (study product)\n* known allergy to hair dye, or hair dye components\n* clinically relevant history of hypotension\n* untreated or uncontrolled hypertension\n* pregnant, planning a pregnancy or nursing a child\n* history of hair transplants\n* currently use hair weaves or non-breathable wigs\n* dermatologic disorders of the scalp that require chronic use of medication for control\n* other types or history of hair loss\n* enrolled in any other investigational medication (drug) study currently, or within the last 6 months","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Target Area Hair Count","description":"Number of hairs in the area being examined as measured by macrophotography.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152.7","spread":"59.7"},{"groupId":"OG001","value":"158.6","spread":"61.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"162.2","spread":"63.1"},{"groupId":"OG001","value":"175.7","spread":"65.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"16.2"},{"groupId":"OG001","value":"13.5","spread":"22.3"}]}]}]},{"type":"SECONDARY","title":"Target Area Hair Count","description":"Number of hairs in the area being examined as measured by macrophotography.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152.7","spread":"59.7"},{"groupId":"OG001","value":"158.6","spread":"61.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"163.3","spread":"63.2"},{"groupId":"OG001","value":"178.1","spread":"66.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":"15.3"},{"groupId":"OG001","value":"16.4","spread":"21.5"}]}]}]},{"type":"PRIMARY","title":"Subject Assessment of Scalp Coverage","description":"Subject assessment of scalp coverage at Week 24 was measured as change from Baseline on a 7-point scale where 0 meant no perceived change in scalp coverage, +1 to +3 indicated progressively increased levels of scalp coverage, and -1 to -3 indicated progressively decreased levels.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"1.66"},{"groupId":"OG001","value":"0.74","spread":"1.71"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":201},"commonTop":["Weight Increased","Nasopharyngitis","Headache","Upper Respiratory Tract Infection","Sinusitis"]}}}